Your new post is loading...
Bertilimumab is a fully human, IgG4-type monoclonal antibody (mAb) that blocks the activity of a protein called eotaxin-1 that plays an important role in inflammation in multiple clinical indications.
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
Immune Pharmaceuticals Inc., a clinical stage bio-pharmaceutical company with a monoclonal antibody, bertilimumab, for the treatment of auto-immune diseases, and STC Biologics, a biotechnology development company led by alumni of Genentech, Shire, Novartis and Merrimack Pharmaceuticals, announced today that they are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics.